Stem Cells for Safer Medicine

Drug companies are growing miniature human livers in the lab from stem cells to test whether new drug candidates will poison patients before they ever reach a clinical trial. Liver toxicity is one of the most common reasons promising drugs fail during development, often after years of investment. Current safety tests rely on animal cells or simple cell cultures that do not reliably predict how a human liver will react. This consortium of pharmaceutical companies and academic labs aims to replace those crude screens with living human liver-like cells—called hepatocytes—grown from pluripotent stem cells. The challenge is making those lab-grown cells behave like real adult liver cells, responding to drugs in the same way a patient’s liver would. If the consortium succeeds, drug developers could spot toxic compounds earlier, before expensive animal studies and human trials. That would reduce the number of late-stage drug failures, cut development costs, and—most importantly—prevent patients from being exposed to dangerous side effects. The project is also building automated, high-throughput screening platforms so the tests can be integrated into the standard industrial pipelines that pharmaceutical companies already use to evaluate thousands of compounds.